share_log

Adial Pharmaceuticals | D: Filing D

Adial Pharmaceuticals | D: Filing D

Adial Pharmaceuticals | D：发行公告
美股SEC公告 ·  03/15 05:16

Moomoo AI 已提取核心信息

Adial Pharmaceuticals, Inc., a biopharmaceutical company based in Glen Allen, Virginia, has filed a Form D Notice of Exempt Offering of Securities with the Securities and Exchange Commission (SEC). The filing, dated March 14, 2024, indicates that the company has successfully raised $287,500 through an equity offering. The offering, which includes options, warrants, or other rights to acquire another security, was made under Rule 506(b) of the Securities Act, exempting it from registration requirements. The first sale of the securities occurred on March 6, 2024, and the offering is not intended to last more than one year. Adial Pharmaceuticals has declined to disclose the issuer size by revenue or aggregate net asset value. The company has also stated that none of the proceeds from the...Show More
Adial Pharmaceuticals, Inc., a biopharmaceutical company based in Glen Allen, Virginia, has filed a Form D Notice of Exempt Offering of Securities with the Securities and Exchange Commission (SEC). The filing, dated March 14, 2024, indicates that the company has successfully raised $287,500 through an equity offering. The offering, which includes options, warrants, or other rights to acquire another security, was made under Rule 506(b) of the Securities Act, exempting it from registration requirements. The first sale of the securities occurred on March 6, 2024, and the offering is not intended to last more than one year. Adial Pharmaceuticals has declined to disclose the issuer size by revenue or aggregate net asset value. The company has also stated that none of the proceeds from the offering will be used to make payments to its executive officers, directors, or promoters. The sole investor in the offering is not an accredited investor, and sales commissions of $23,000 were estimated to be paid to H.C. Wainwright & Co., LLC. The company specializes in the pharmaceuticals sector within the healthcare industry and is incorporated in Delaware.
总部位于弗吉尼亚州格伦艾伦的生物制药公司Adial Pharmicals, Inc. 已向美国证券交易委员会（SEC）提交了D表豁免证券发行通知。这份日期为2024年3月14日的文件显示，该公司已通过股票发行成功筹集了287,500美元。此次发行包括期权、认股权证或其他收购其他证券的权利，是根据《证券法》第506（b）条进行的，免除了注册要求。证券的首次出售发生在2024年3月6日，本次发行的持续时间不超过一年。Adial Pharmicals拒绝按收入或总净资产价值披露发行人规模。该公司还表示，此次发行的收益均不会用于向其执行官、董事或发起人付款。此次发行的唯一投资者不是合格投资者，估计将向H.C. Wainwright & Co., LLC支付23,000美元的销售佣金。该公司专门从事医疗保健行业的制药行业，并在特拉华州注册成立。
总部位于弗吉尼亚州格伦艾伦的生物制药公司Adial Pharmicals, Inc. 已向美国证券交易委员会（SEC）提交了D表豁免证券发行通知。这份日期为2024年3月14日的文件显示，该公司已通过股票发行成功筹集了287,500美元。此次发行包括期权、认股权证或其他收购其他证券的权利，是根据《证券法》第506（b）条进行的，免除了注册要求。证券的首次出售发生在2024年3月6日，本次发行的持续时间不超过一年。Adial Pharmicals拒绝按收入或总净资产价值披露发行人规模。该公司还表示，此次发行的收益均不会用于向其执行官、董事或发起人付款。此次发行的唯一投资者不是合格投资者，估计将向H.C. Wainwright & Co., LLC支付23,000美元的销售佣金。该公司专门从事医疗保健行业的制药行业，并在特拉华州注册成立。
有用
没用

该公告为独立文件：

独立文件1  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    热议
    美股
    股票代码最新价涨跌幅

    暂无数据

    资讯热榜
    更新时间